DOI: 10.36347/sjams.2018.v06i12.026

Pages: 4757-4763

All pharmacological interventions balance efficacy and toxicity; there are few efficacious agents that do not have some toxicity risk. In the case of antituberculosis agents the major risk is hepatotoxicity and three agents identified by World Health Organization (WHO) as essential, isoniazid (INH), rifampicin (RMP) and pyrazinamide (PZA), carry such a risk. The liver is vulnerable to injury from the first line anti-tuberculosis drugs. This may result in mortality, long term morbidity and reduced compliance to therapy. A prospective study of 100 cases was done in this study. The cases were divided into two broad groups. Group A comprised control of 25 children and Group B comprised different varieties of tuberculosis patient with 75 children.